Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders

Stress exposure is associated with psychiatric conditions, such as depression, anxiety, and post-traumatic stress disorder (PTSD). It is also a vulnerability factor to developing or reinstating substance use disorder. Stress causes several changes in the neuro-immune-endocrine axis, potentially resulting in prolonged dysfunction and diseases. Changes in several transmitters, including serotonin, dopamine, glutamate, gamma-aminobutyric acid (GABA), glucocorticoids, and cytokines, are associated with psychiatric disorders or behavioral alterations in preclinical studies. Complex and interacting mechanisms make it very difficult to understand the physiopathology of psychiatry conditions; therefore, studying regulatory mechanisms that impact these alterations is a good approach. In the last decades, the impact of stress on biology through epigenetic markers, which directly impact gene expression, is under intense investigation; these mechanisms are associated with behavioral alterations in animal models after stress or drug exposure, for example. The endocannabinoid (eCB) system modulates stress response, reward circuits, and other physiological functions, including hypothalamus-pituitary-adrenal axis activation and immune response. eCBs, for example, act retrogradely at presynaptic neurons, limiting the release of neurotransmitters, a mechanism implicated in the antidepressant and anxiolytic effects after stress. Epigenetic mechanisms can impact the expression of eCB system molecules, which in turn can regulate epigenetic mechanisms. This review will present evidence of how the eCB system and epigenetic mechanisms interact and the consequences of this interaction in modulating behavioral changes after stress exposure in preclinical studies or psychiatric conditions. Moreover, evidence that correlates the involvement of the eCB system and epigenetic mechanisms in drug abuse contexts will be discussed.

Localized endocytosis in tobacco pollen tubes: visualisation and dynamics of membrane retrieval by a fluorescent phospholipid

Two modes of endocytosis are known to occur in eucaryotic cells: fluid phase and receptor-mediated endocytosis. Fluid-phase endocytosis in plant cells resembles the retrieval of excess plasma membrane material previously incorporated by exocytosis. Pollen tubes need to carry out strong membrane retrieval due to their fast polar tip growth. Plasma membrane labelling of pollen tubes, grown in suspension, was achieved by the incorporation of a fluorescently modified phospholipid, 1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine (20 microM) and measured with a confocal laser-scanning microscope. Time course experiments revealed a highly localised and relatively fast plasma membrane retrieval below the tip within the first 5 min after phospholipid application. The retrieved fluorescent plasma membrane was quickly re-integrated into parts of the endomembrane pool and then redistributed to the pollen tube base and very tip of the apex, with the exception of the cortical endoplasmic reticulum (ER) and the mitochondria even after 1-h incubation period. Low temperature (10 degrees C) and the actin filament depolymerizing cytochalasin D (2 microM) completely abolished plasma membrane retrieval, whereas the microtubule destabilizing herbicide oryzalin (1 microM) had no effect. Our results provide strong support for a highly localised endocytotic pathway in tobacco pollen tubes. Passive uptake of bis-Bodipy FL C(11)-phosphocholine by mere penetration can be excluded. It is a valuable alternative to the styryl dyes often used in endocytotic studies, and may also be used to follow lipid turnover because membrane flow of labelled membranes occurs apparently not in a default manner as ascertained by its fast distribution.

SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23)

We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2;11)(q37;q23) as the only cytogenetic abnormality. Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL. RNA and DNA analyses showed the existence of an in-frame fusion of MLL exon 7 with SEPT2 exon 3, with the genomic breakpoints located in intron 7 and 2 of MLL and SEPT2, respectively. Search for DNA sequence motifs revealed the existence of two sequences with 94.4% homology with the topoisomerase II consensus cleavage site in MLL intron 7 and SEPT2 intron 2. SEPT2 is the fifth septin family gene fused with MLL, making this gene family the most frequently involved in MLL-related AML (about 10% of all known fusion partners). The protein encoded by SEPT2 is highly homologous to septins 1, 4 and 5 and is involved in the coordination of several key steps of mitosis. Further studies are warranted to understand why the septin protein family is particularly involved in the pathogenesis of MLL-associated leukemia.